Tumor Biology

, 32:1155 | Cite as

Evaluation of multiple serum markers in advanced melanoma

  • Angel Díaz-Lagares
  • Estíbaliz Alegre
  • Ainhoa Arroyo
  • María González-Cao
  • Maria E. Zudaire
  • Santiago Viteri
  • Salvador Martín-Algarra
  • Alvaro GonzálezEmail author
Research Article


The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.


Melanoma Tumour markers S-100B MIA LDH Survival Metastasis 



American Joint Committee on Cancer


Melanoma inhibitory activity protein


Area under curve



A.D.L is funded by the Xunta de Galicia through a research-staff contract “Angeles Alvariño”.


  1. 1.
    Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46:270–83PubMedCrossRefGoogle Scholar
  2. 2.
    Brochez L, Naeyaert J-M (2000) Serological markers for melanoma. British J Dermatol 143:256–68CrossRefGoogle Scholar
  3. 3.
    Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G (2010) Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v194–7PubMedCrossRefGoogle Scholar
  4. 4.
    Jennings L, Murphy GM (2009) Predicting outcome in melanoma: where are we now? Br J Dermatol 161:496–503PubMedCrossRefGoogle Scholar
  5. 5.
    Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 19:3635–48PubMedGoogle Scholar
  6. 6.
    Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C (2010) Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 163:238–56PubMedCrossRefGoogle Scholar
  7. 7.
    Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17:2417–25PubMedCrossRefGoogle Scholar
  8. 8.
    Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N, Reintgen D (1996) Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3:558–63PubMedCrossRefGoogle Scholar
  9. 9.
    Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–53PubMedGoogle Scholar
  10. 10.
    Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL (1998) Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 187:191–7PubMedCrossRefGoogle Scholar
  11. 11.
    Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106:1130–9PubMedCrossRefGoogle Scholar
  12. 12.
    Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA (1997) Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 137:381–5PubMedCrossRefGoogle Scholar
  13. 13.
    Gogas H, Eggermont AMM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R (2009) Biomarkers in melanoma. Ann Oncol 20:vi8–13PubMedCrossRefGoogle Scholar
  14. 14.
    Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37:512–8PubMedCrossRefGoogle Scholar
  15. 15.
    Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW (2008) Immunohistochemical characteristics of melanoma. J Cutan Pathol 35:433–44PubMedCrossRefGoogle Scholar
  16. 16.
    Bosserhoff AK, Hein Rd, Bogdahn U, Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271:490–5PubMedCrossRefGoogle Scholar
  17. 17.
    Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, A New prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194–202PubMedCrossRefGoogle Scholar
  18. 18.
    Krause S, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis J, Andreesen R (1996) Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukocyte Biol 60:540–5PubMedGoogle Scholar
  19. 19.
    Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M (2001) Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 20:192–6PubMedCrossRefGoogle Scholar
  20. 20.
    Shackelton LM, Mann DM, Millis AJ (1995) Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270:13076–83PubMedCrossRefGoogle Scholar
  21. 21.
    Johansen JS, Bojesen SE, Tybjaerg-Hansen A, Mylin AK, Price PA, Nordestgaard BG (2010) Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 56:1580–91PubMedCrossRefGoogle Scholar
  22. 22.
    Johansen JS, Jensen BV, Roslind A, Price PA (2007) Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets 11:219–34PubMedCrossRefGoogle Scholar
  23. 23.
    Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891–6PubMedGoogle Scholar
  24. 24.
    Cao MG, Auge JM, Molina R, Marti R, Carrera C, Castel T, Vilella R, Conill C, Sanchez M, Malvehy J, Puig S (2007) Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res 27:595–9PubMedGoogle Scholar
  25. 25.
    Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Bricon TL (2007) Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43:816–21PubMedCrossRefGoogle Scholar
  26. 26.
    Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A (2008) Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31:380–4PubMedCrossRefGoogle Scholar
  27. 27.
    Dummer R, Panizzon R, Bloch PH, Burg G (2005) Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 210:39–44PubMedCrossRefGoogle Scholar
  28. 28.
    Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A (2008) Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 6:S9–14PubMedCrossRefGoogle Scholar
  29. 29.
    Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU (2001) S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastasis compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 21:1311–6PubMedGoogle Scholar
  30. 30.
    Garbe C, Leiter U, Ellwanger U, Blaheta H-J, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97:1737–45PubMedCrossRefGoogle Scholar
  31. 31.
    Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL (2007) A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Investigation 25:285–93PubMedCrossRefGoogle Scholar
  32. 32.
    Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–44PubMedCrossRefGoogle Scholar
  33. 33.
    Auge JM, Molina R, Filella X, Bosch E, Cao MG, Puig S, Malvehy J, Castel T, Ballesta AM (2005) S-100B and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res 25:1779–82PubMedGoogle Scholar
  34. 34.
    Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209PubMedGoogle Scholar
  35. 35.
    Siekmann L, Bonora R, Burtis CA, Ceriotti F, Clerc-Renaud P, Ferard G, Ferrero CA, Forest JC, Franck PF, Gella FJ, Hoelzel W, Jorgensen PJ, Kanno T, Kessner A, Klauke R, Kristiansen N, Lessinger JM, Linsinger TP, Misaki H, Mueller MM, Panteghini M, Pauwels J, Schiele F, Schimmel HG, Vialle A, Weidemann G, Schumann G (2002) IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 7. Certification of four reference materials for the determination of enzymatic activity of gamma-glutamyltransferase, lactate dehydrogenase, alanine aminotransferase and creatine kinase accord. Clin Chem Lab Med 40:739–45PubMedCrossRefGoogle Scholar
  36. 36.
    Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ (2009) S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 16:3455–62PubMedCrossRefGoogle Scholar
  37. 37.
    Hofmann MA, Gussmann F, Fritsche A, Biesold S, Schicke B, Kuchler I, Voit C, Trefzer U (2009) Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res 19:17–23PubMedCrossRefGoogle Scholar
  38. 38.
    Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27:38–44PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  • Angel Díaz-Lagares
    • 1
    • 2
  • Estíbaliz Alegre
    • 1
  • Ainhoa Arroyo
    • 1
  • María González-Cao
    • 4
  • Maria E. Zudaire
    • 3
  • Santiago Viteri
    • 4
  • Salvador Martín-Algarra
    • 3
  • Alvaro González
    • 1
    Email author
  1. 1.Laboratory of BiochemistryUniversity Clinic of NavarraPamplonaSpain
  2. 2.Fundación Pública Galega de Medicina XenómicaSantiago de CompostelaSpain
  3. 3.Department of Medical OncologyUniversity Clinic of NavarraPamplonaSpain
  4. 4.Medical Oncology Department, Instituto Oncológico Dr Rosell—Pangaea BiotechInstituto Universitari DexeusBarcelonaSpain

Personalised recommendations